Teil 5 von 14
April, 2006:
* HHS announces a $97 million contract for the development of cell-based flu vaccine.
* Leavitt declares: “The FDA can use its Emergency Use Authorization authority to permit the use of unapproved products if there’s a reasonable belief the products may be effective.”
* 32 states pass laws which make resisting inocculation once ordered by the governor a felony.
* These laws join Patriot Act I, II, BARDA, BIOSHIELD I, II in making drug treatment and innoculation mandatory once a Pandemic is called.
* Unlimited quarantine without review is mandated under these laws for those who resist innoculation under Pandemic conditions.
* Fully staffed, empty detention centers exist all over North America. The largest, in Alasks, is roumored to have a 2.5 million person capacity.
December, 2006:
* New York Times reports Gulf War Syndrome positively linked to vaccination of Veterans.
* More than 100,000 vets contracted the syndrome during the 1991 Desert Storm Operation.
* More than 20,000 vets have died to date from this syndrom believed to be triggered by squalene, a vaccine “adjuvant.”
* All modern vaccines contain squalene
April 17, 2007:
* The Food and Drug Adminstration (FDA) branch of HHS utilizes its Emergency Use Authorization authority and awards a license to produce H5N1 “Bird Flu” vaccines to Sanofi-Pasteur.
* FDA Bird Flu approval letter states:
“We have approved your Biologics License Application (BLA) for Influenza Virus Vaccine, H5N1, effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Influenza Virus Vaccine, H5N1, under your existing Department of Health and Human Services U.S. License No. 1725; however, we acknowledge your statement provided in your submission of April 5, 2007, that Sanofi Pasteur Inc. does not intend to license this product for commercial distribution, since it was produced under contract to the U.S. Department of Health and Human Services as part of national pandemic preparedness initiatives. Influenza Virus Vaccine, H5N1, is indicated for active immunization of persons 18 through 64 years of age at increased risk of exposure to the H5N1 influenza virus subtype contained in the vaccine.”
* Among the required post-market studies on this untested vaccine are;
1. Protocol submission: Study DMID 04-077: “A randomized, double-blinded, phase I/II, study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine in healthy children aged 2 years through 9 years.”
2. Final study report submission: September 30, 2008.Study DMID 04-076: “A randomized double-blinded, placebo-controlled, phase I/II, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine in healthy elderly adults.”
3. Study DMID 05-0043: “Revaccination of healthy subjects with intramuscular inactivated subunit influenza A/Vietnam/1203/2004 (H5N1) vaccine representing a drifted variant.
4. “Study DMID 05-0090: “Evaluation of a booster dose of A/Vietnam/1203/04 (H5N1) vaccine administered at 6 months to healthy adult subjects after a two dose schedule at 0 and 1 month.”
5. Study DMID 05-0129: “Open label evaluation of H5N1 vaccine at vaccine manufacturing facilities.”
6. Study DMID 05-0130: “A single center, open label, phase I/II study of the safety and immunogenicity of two 90 µg doses of intramuscular inactivated influenza A/H5N1 vaccine in healthy adult subjects.”
Nov. 26, 2007:
* Leavitt’s HHS orders 100 million H5N1 “vaccines [doses]” from Sanofi-Pasteur. Expected delivery date, August, 2008.
* Sanofi-Pasteur issues a press release announcing their lucrative HHS contract (100 million vaccines @ $15 USD each) and declares that the cell-based vaccine will be mass produced in the company’s CHINA facility – then shipped to Stillwater, PA for hypodermic syringe-friendly packaging.
* Approval and contract have all been consumated in the absence of offical human testing.
April, 2006:
* HHS announces a $97 million contract for the development of cell-based flu vaccine.
* Leavitt declares: “The FDA can use its Emergency Use Authorization authority to permit the use of unapproved products if there’s a reasonable belief the products may be effective.”
* 32 states pass laws which make resisting inocculation once ordered by the governor a felony.
* These laws join Patriot Act I, II, BARDA, BIOSHIELD I, II in making drug treatment and innoculation mandatory once a Pandemic is called.
* Unlimited quarantine without review is mandated under these laws for those who resist innoculation under Pandemic conditions.
* Fully staffed, empty detention centers exist all over North America. The largest, in Alasks, is roumored to have a 2.5 million person capacity.
December, 2006:
* New York Times reports Gulf War Syndrome positively linked to vaccination of Veterans.
* More than 100,000 vets contracted the syndrome during the 1991 Desert Storm Operation.
* More than 20,000 vets have died to date from this syndrom believed to be triggered by squalene, a vaccine “adjuvant.”
* All modern vaccines contain squalene
April 17, 2007:
* The Food and Drug Adminstration (FDA) branch of HHS utilizes its Emergency Use Authorization authority and awards a license to produce H5N1 “Bird Flu” vaccines to Sanofi-Pasteur.
* FDA Bird Flu approval letter states:
“We have approved your Biologics License Application (BLA) for Influenza Virus Vaccine, H5N1, effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Influenza Virus Vaccine, H5N1, under your existing Department of Health and Human Services U.S. License No. 1725; however, we acknowledge your statement provided in your submission of April 5, 2007, that Sanofi Pasteur Inc. does not intend to license this product for commercial distribution, since it was produced under contract to the U.S. Department of Health and Human Services as part of national pandemic preparedness initiatives. Influenza Virus Vaccine, H5N1, is indicated for active immunization of persons 18 through 64 years of age at increased risk of exposure to the H5N1 influenza virus subtype contained in the vaccine.”
* Among the required post-market studies on this untested vaccine are;
1. Protocol submission: Study DMID 04-077: “A randomized, double-blinded, phase I/II, study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine in healthy children aged 2 years through 9 years.”
2. Final study report submission: September 30, 2008.Study DMID 04-076: “A randomized double-blinded, placebo-controlled, phase I/II, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine in healthy elderly adults.”
3. Study DMID 05-0043: “Revaccination of healthy subjects with intramuscular inactivated subunit influenza A/Vietnam/1203/2004 (H5N1) vaccine representing a drifted variant.
4. “Study DMID 05-0090: “Evaluation of a booster dose of A/Vietnam/1203/04 (H5N1) vaccine administered at 6 months to healthy adult subjects after a two dose schedule at 0 and 1 month.”
5. Study DMID 05-0129: “Open label evaluation of H5N1 vaccine at vaccine manufacturing facilities.”
6. Study DMID 05-0130: “A single center, open label, phase I/II study of the safety and immunogenicity of two 90 µg doses of intramuscular inactivated influenza A/H5N1 vaccine in healthy adult subjects.”
Nov. 26, 2007:
* Leavitt’s HHS orders 100 million H5N1 “vaccines [doses]” from Sanofi-Pasteur. Expected delivery date, August, 2008.
* Sanofi-Pasteur issues a press release announcing their lucrative HHS contract (100 million vaccines @ $15 USD each) and declares that the cell-based vaccine will be mass produced in the company’s CHINA facility – then shipped to Stillwater, PA for hypodermic syringe-friendly packaging.
* Approval and contract have all been consumated in the absence of offical human testing.
